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CLINICAL FACTORS ASSOCIATED WITH SERUM COPPER CONCENTRATION
IN PATIENTS ON HEMODIALYSIS
Ryota Ikee, Masataka Tsunoda, Naomi Sasaki, Megumi Sato,
Nobuo Hashimoto
H. N. Medic Kitahiroshima, Kitahiroshima, Hokkaido, Japan
It is well known that renal insufﬁciency inﬂuences trace element
metabolism. In particular, patients treated with hemodialysis (HD) are at
higher risk for both deﬁciency and excess of trace elements. However,
derangements of serum trace element levels reported by previous studies
were sometimes inconsistent. In addition, harmful effects by trace element
derangements seem quite unclear.
In this cross-sectional study, we examined clinical factors associated
with serum copper levels in patients treated with HD for more than or
equal to 6 months.
In 49 patients (male : female ¼29 : 20, age 71 7 10 years, HD duration
84 7 71 months), the mean value of serum copper was 93.8 7 16.2 mg/dL.
In univariate analysis, there were no signiﬁcant correlation between serum
copper levels and patient’s age, sex, HD duration, the presence of diabetes
mellitus, serum albumin levels, and body mass index. Serum copper levels
signiﬁcantly correlated with serum levels of high-sensitivity C-reactive
protein (hs-CRP; r¼0.474, P¼0.001) and malondialdehyde-low-density
lipoprotein (r¼0.371, P¼0.009). It was notable that serum copper levels
tended to be lower in those treated with higher dose of sevelamer
hydrochloride (r¼0.255, P¼0.07). In multivariate analysis, hs-CRP
remained to be an independent determinant of serum copper levels.
We showed signiﬁcant association of serum copper levels with
inﬂammation and oxidative stress in HD patients. Further studies are
required to investigate whether sevelamer may improve serum copper
levels, inﬂammation, and oxidative stress.
http://dx.doi.org/10.1016/j.krcp.2012.04.410
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MODIFIED MIS SHEET IS DESIRABLE FOR THE NST ACTIVITY ON CHRONIC
DIALYSIS PATIENTS
Ikuto Masakane 1, Miho Suzuki 1, Mika Nakajima 1, Yumiko Seino 2,
Kiyotaka Yabuki 2
1
Yabuki Shima Clinic, Japan
2
Yabuki Hospital, Yamagata, Japan
Nutritional status is the most important factor which guarantees long
survival with higher quality of life on chronic dialysis patients. Various
procedures for evaluating nutritional status have been proposed but the
standard of them has not been established. We modiﬁed the MIS sheet, which
was originally established by Kalantar-Zadeh, by adding some parameters as
CRP, nPCR and the dialysis prescription on the same sheet.
We have performed NST activity using the modiﬁed MIS sheet twice a year
for recent 6 years. We categorize the patients into the next three groups based
on total point of MIS; Normal, Mild malnourished and moderately/severely
malnourished. The patient survival in each group could be clearly identiﬁed
from each other. The causes of malnutrition were categorized as inﬂammatory
type, mal-dietary type and mixed type. Therapeutic interventions were
inducted for each type; those were a treatment for pyorrhea, foot care and a
dialysis prescription change. Dietitians interviewed the patients with mal-
dietary type malnutrition and their families. Every six months, we repeatedly
evaluated the nutritional status of the patients and determined whether our
interventions had succeeded.
Our modiﬁed MIS sheet is not only a screening tool but a practical tool by
which we can make a therapeutic plan for various types of malnutrition.
Our preliminary results clariﬁed that the interventions derived from the
MIS system could signiﬁcantly improve the total score of MIS. In conclusion
the modiﬁed MIS sheet is desirable for a daily NST activity on chronic dialysis
patients.
http://dx.doi.org/10.1016/j.krcp.2012.04.411
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PROTEIN CATABOLIC RATE SHOULD BE NORMALIZED BY IDEAL BODY
WEIGHT NOT BY POST-DIALYSIS BODY WEIGHT.
Ikuto Masakane 1, Mika Nakajima 1, Miho Suzuki 1, Yumiko Seino 2,
Kiyotaka Yabuki 2
1
Yabuki Shima Clinic
2
Yabuki Hospital Yamagata Japan
Protein catabolic rate (PCR) is calculated by urea kinetic model thorough
the dialysis session and it is recognized as expressing the protein intake in
the steady state of dialysis patients. PCR is generally normalized by post-
dialysis body weight (BW), expressed as nPCR, however, most dietary
guidelines for protein intake are documented as PCR normalized by ideal
BW (iPCR). We evaluated which is better nPCR or iPCR to estimate the
impact on the patient survival and to use it for dietary education for
dialysis patients.
119 chronic dialysis patients whose dialysis vintages were longer than
3 years were selected into this study. The mean age of them was 62.4years
old and the mean dialysis vintage was 115.4 months. The patients were
divided into 4 groups by each PCR value as less than 0.7, 0.7– 0.9, 0.9–1.1,
greater than 1.1 g/Kg/day. Kaplan-Meier analysis was conducted to
evaluate the 5–year patient survival in each PCR method. The difference in
the patient survival between 4 groups in each PCR method was evaluated
by Log-rank test.
Among 119 patients 30 patients died and 9 patients were censored out,
and the overall 5-year survival rate was 74.4%. There were no signiﬁcant
differences between 4 groups in nPCR. However, a signiﬁcant risk in the
group less than 0.7 g/Kg/day and a signiﬁcant beneﬁt in the group greater
than 1.1 g/Kg/day were observed in iPCR. Both nPCR and iPCR were not
independent signiﬁcant risk factor on the patient survival. Only age and the
serum level of CRP were signiﬁcant risk factor. We concluded the PCR
should be normalized by ideal BW not by post-dialysis BW.
http://dx.doi.org/10.1016/j.krcp.2012.04.412
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EFFECTS OF SOY CONSUMPTION ON SERUM LIPIDS AND APOPROTEINS
IN PERITONEAL DIALYSIS PATIENTS: A RANDOMIZED
CONTROLLED TRIAL
Hossein Imani, Tabibi Hadi, Atabak Shahnaz, Rahmani Leila
Lipid abnormalities, particularly high serum concentration of
lipoprotein(a) [Lp(a)], are one of the major risk factors for cardiovascular
disease (CVD) in peritoneal dialysis (PD) patients. The present study was
designed to investigate the effects of soy consumption on serum lipids
and apoproteins, especially Lp(a), in PD patients .This study was a
randomized clinical trial in which 40 PD patients (20 males, 20 females)
were randomly assigned to either the soy or the control group. Patients
in the soy group received 28 g/day textured soy ﬂour (containing 14 g of
soy protein) for 8 weeks, whereas patients in the control group received
their usual diet, without any soy. At baseline and the end of week 8 of
the study, 5 mL of blood was collected from each patient after a 12- to
14-hour fast and serum triglyceride, total cholesterol, low density
lipoprotein-cholesterol (LDL-C), high density lipoprotein-cholesterol
(HDL-C), apoprotein B100 (apo B100) apoprotein A (apo AI), and
Lp(a) were measured.
In the present study, serum Lp(a) concentrations were above the
normal range in 86% of the PD patients. Mean serum Lp(a) concentration
was reduced signiﬁcantly, by 41%, in the soy group at the end of week
8 compared to baseline (p o 0.01); the reduction was also signiﬁcant
compared to the control group ( p o 0.05). During the study, mean
serum Lp(a) concentration did not change signiﬁcantly in the control
group. There were no signiﬁcant differences between the two groups in
mean changes in serum triglyceride, total cholesterol, HDL-C, LDL-C,
apoB100, or apoAI.
The results of our study indicate that soy consumption reduces serum
Lp(a) concentration, which is a risk factor for cardiovascular disease in
peritoneal dialysis patients.
http://dx.doi.org/10.1016/j.krcp.2012.04.413
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FERRIC CITRATE: AN IRON-BASED ORAL PHOSPHATE BINDER
T. Christopher Bond, Rich Mutell, Stephen Wang, Enrique Poradosu, Robert
Niecestro Tracy
Mayne DaVita Clinical Research, Minneapolis,
Minnesota, USA, and Keryx Biopharmaceuticals, New York, New York, USA
Patients with end-stage renal disease (ESRD) often experience secondary
bone and mineral disorder requiring treatment with phosphate-binder (PB)
medications, vitamin D sterols, and calcimimetics. Ferric citrate is an oral,
iron-based PB in clinical development that has been shown to reduce
serum phosphorus while increasing serum ferritin and transferrin
saturation (TSAT) in ESRD patients. In a Phase 2 study, patients receiving
Kidney Res Clin Pract 31 (2012) A16–A96A38
ferric citrate experienced signiﬁcant increases in serum ferritin (þ10%) and
TSAT (þ18%) after 4 weeks of treatment.
We analyzed electronic medical records of patients with concurrent rises
in TSAT (Z 10%) and ferritin (15% to 25%) between 6/1/08 and 12/31/10,
excluding patients with signiﬁcant change in iron or erythropoiesis-
stimulating agent (ESA) dose, hemoglobin, or change in PB during the prior
month. We assessed changes in epoetin alfa and iron dosing when
physicians observed these increases in lab values. We constructed a cost
offset model from a per patient per month (PPPM) considering average
sales price of epoetin and iron that assumed equivalent phosphorus
outcomes and pricing across all PB.
The analysis included 2,037 concurrent, non-treatment related rises in
ferritin and TSAT. Decreases in dose/dialysis session in mean epoetin and
iron use 2 months following the index date represented an average
combined savings of $90.51 to $181.01 PPPM. The model was most
sensitive to baseline drug doses: patients at highest baseline epoetin doses
(4 9,000U/session) showed savings of $471.80 to $943.61 PPPM.
Based on actual physician behavior in response to ferritin and TSAT
increases and ferric citrate clinical trial results, and assuming equivalent
pricing to other PBs, there would be cost savings with ferric citrate use
through reduced ESA and iron use.
http://dx.doi.org/10.1016/j.krcp.2012.04.414
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EFFECT OF ASCORBIC ACID ON EPO-HYPORESPONSIVE ANEMIA IN
HEMODIALYSIS PATIENTS
Jimin Jeon, Yongki Park
Dong Rae Bong Seng Hospital, Busan, Korea
We performed the present study to evaluate the efﬁcacy of intravenous
and oral ascorbic acid in improving anemia and iron availability on EPO-
hyporesponsive anemia in hemodialysis patients with hyperferritinemia.
This study of three months duration was conducted in 49 patients with Hb
o11 g/dL and ferritin levels greater than 300 ng/ml. Blood samples for
measurement of Hb, Hct, serum iron, ferritin, TIBC, transferrin saturation,
EPO dose were obtained after baseline and at the end of study after three
months. Patients were randomly divided into three groups. 16 patients had
received standard care(group 1), 17 patients had received standard care
and daily oral ascorbic acid at a dose of 500 mg/day(group 2), and 16
patients had received standard care and 300mg of intravenous vitamin C
with each dialysis session(group 3). Forty-seven patients completed the
study. All of patients dialyzed 4 hours, 3 times a week with similar kt/V.
Hb, serum iron, serum ferritin, transferrin saturation and EPO dose was
similar in the three groups at baseline. After 3 month, Hemoglobin and
hematocrit and transferrin saturation signiﬁcantly increased in group 2,3.
but not changed in group 1. EPO dose and ferritin level decreased in group
2,3. but not changed in group 1. There was no difference between group
2 and 3. In conclusion, intravenous or oral ascorbic acid therapy can
improve hyperferritinemia and EPO hyporesponsive anemia in
hemodialysis patients. And The effect of intravenous and oral ascorbic acid
are similar.
http://dx.doi.org/10.1016/j.krcp.2012.04.415
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IMPACT OF RENAL TRANSPLANTATION ON BODY COMPOSITION
AC Johansson, E Johansson, A Weibull, M Hansson, S Mattsson
Skane University Hospital, Malmo, Sweden
The aim of the study was to analyse the impact of renal transplantation
on body composition (Body Cell Mass) in adult kidney transplant
recipients.Body Cell Mass (BCM) was calculated from total body potassium
(TBK), determined from K-40 in a whole body counter. Patients were
measured before transplantation and 3 months, 1 year and 2 years after
transplantation. Patients were encouraged to take part in physical exercise,
but supervised physical training was not included in the study Out of 50
included patients, 44 have had a kidney transplant (9 F, 35 M). Mean age at
transplantation was 49 (23-72) years. Before transplantation, mean BW
was 80 (SD 13) kg and mean BMI 25,6 (SD 4) kg/m2. Mean TBK was 3162
(SD 690) mmol, corresponding to 90 % of predicted value. In the 1 year
follow up, no signiﬁcant changes in TBK (n¼42) were found, nor in patients
examined 2-3 years after transplantation (n¼35). To examine whether
post transplantation improvement of BCM will appear later, as has been
seen in Liver Transplant recipients, patients were invited to a follow up
measurement. So far, 11 patients have repeated the measurement 6 (4½-
7½) years after transplantation. TBK improvements of 410% were seen in
4 patients, decreases of 410% in 2 patients, and changes of a lower
magnitude in remaining patients. In conclusion, no increase in Body Cell
Mass was seen in this unselected group of kidney transplant recipients
during the ﬁrst 2-3 years after transplantation. Pro catabolic events and
low physical activity may explain this lack oﬁmprovement.
http://dx.doi.org/10.1016/j.krcp.2012.04.416
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SODIUM INTAKE AND RISK OF CORONARY HEART DISEASE IN THE
OVERALL POPULATION AND SPECIFIC SUBPOPULATIONS
Michel Joosten, Ron Gansevoort, Hiddo Lambers Heerspink,
Johanna Geleijnse, Edith Feskens, Gerjan Navis
Stephan Bakker. Department of Internal Medicine, UMCG, Groningen, the
Netherlands & Top Institute Food & Nutrition, Wageningen, the Netherlands.
Whether excess sodium intake is a risk factor for coronary heart disease
(CHD) has recently been challenged, despite compelling evidence for its
adverse effects on blood pressure and extracellular volume. We examined
the association between sodium intake and risk of CHD in the overall
population and in subgroups potentially more susceptible to the
detrimental effects of high sodium intake.
We included 7779 adults without previous cardiovascular diseases or
cancer at baseline (1997-1998) from the observational, community-based
PREVEND study. Sodium intake was estimated from two 24-h urine
collections and normalized to creatinine excretion. Hypertension and
N-Terminal pro-B-type Natriuretic Peptide (NTproBNP) levels above the
sex-speciﬁc median were deﬁned as predisposing factors to the adverse
effects of high sodium intake. We documented 464 events, during a median
follow-up of 10.5 y, There was some evidence for a trend between sodium
intake and risk of CHD in the entire cohort after adjustment for CHD risk
factors [Hazard ratio (HR), 1.06; 95% conﬁdence interval (CI), 0.97-1.17 per
SD increment]. Each SD increment in sodium intake was associated with a
higher risk for CHD only among subjects with hypertension (n¼2453; HR,
1.14; 95% CI, 1.01-1.29) and with elevated NTproBNP levels (n¼3796; HR,
1.14; 95% CI, 1.02-1.28).
In conclusion, a higher sodium intake was associated with an increased
risk of CHD among subjects with hypertension and elevated levels of
Table 1. Baseline and 3 month Data
Group1(n¼16) Group2(n¼17) Group3(n¼14)
baseline After3month baseline After3month baseline After3month
Hb(g/dl 8.9þ1.4 8.8þ1.3 8.8þ1.3 9.5þ1.2 9.0þ1.2 9.6þ1.2
Fe(u/L) 55.84þ23 58.6þ19 58.57þ25 63.7þ22 61.12þ21 6729þ19
EPOdose(unit/week)14729 14538 15584 12369 14986 11345
Ferritin(ug/l) 764þ217 781þ192 783þ191 646þ189 754þ220 634þ231
Transferrin
saturation(%)
18þ6.4 18þ5.8 20.6þ5.5 26.4þ4.4 19.8þ4.9 24.5þ3.2
*is po0.5
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